Compare IGIC & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGIC | ALVO |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | Jordan | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2019 | N/A |
| Metric | IGIC | ALVO |
|---|---|---|
| Price | $25.52 | $3.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $28.00 | $8.00 |
| AVG Volume (30 Days) | 45.5K | ★ 393.6K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.13 | $13.28 |
| Revenue Next Year | $2.54 | $18.63 |
| P/E Ratio | ★ $9.05 | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.82 | $3.03 |
| 52 Week High | $27.43 | $11.85 |
| Indicator | IGIC | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.55 | 46.12 |
| Support Level | $24.29 | $3.10 |
| Resistance Level | $25.50 | $3.83 |
| Average True Range (ATR) | 0.86 | 0.19 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 35.02 | 29.20 |
International General Insurance Holdings Ltd is an international specialty insurance and reinsurance group. It underwrites a diversified portfolio of specialty risks including energy, property, construction and engineering, ports and terminals, general aviation, political violence, professional lines, financial institutions, marine, contingency and treaty reinsurance. The company's operating segments include Specialty Longtail, Specialty Short tail and Reinsurance. The majority of revenue is derived from the Specialty Short-tail segment, which comprises business lines with underwriting risks assumed in the form of property and specialty lines insurance and of short-term nature with respect to related claims.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.